AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...

A growing body of evidence suggests that popular GLP-1 drugs, widely used for weight loss and diabetes, can provide ...

But is the higher incidence of grade 3/4 adverse events "a worthwhile price to pay?" exper ...

Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing ...

AstraZeneca is polishing the case for its Imfinzi (durvalumab) and Imjudo (tremelimumab) combo in liver cancer with a new ...

Oral drug shows responses across 6 tumor types in patients resistant to immunotherapy, with durable benefits and manageable safety in a ...

Significant reductions seen in non-small cell lung cancer, breast cancer, colorectal cancer, and hepatocellular carcinoma.

Obesity has been associated with multiple gastrointestinal cancers, but patients with these malignancies and obesity who have ...

A three-drug regimen incorporating AstraZeneca's immune checkpoint inhibitors Imfinzi and Imjudo has reduced the risk of ...

Readouts in hepatocellular carcinoma, as well as pancreatic, gastric and salivary gland cancer, are capturing attention at ...

Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, ...

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...